We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
JARDIAMET (Boehringer Ingelheim Pty Ltd)
Product name
JARDIAMET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 (255 working days)
Active ingredients
empagliflozin, metformin hydrochloride
Registration type
EOI
Indication
JARDIAMET is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and children aged 10 years and above with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see Sections 4.2 Dose and method of administration and 5.1 Pharmacodynamic properties - Clinical trials).